On July 3, Ruikang Pharmaceutical opened lower. As of press release, it reported 2.97 yuan/share, a decrease of 1.33%. Earlier, Ruikang Pharmaceutical announced the news that Li Zhe, director, board secretary and vice president of the company, had been placed in lien. Regarding questions such as whether Li Zhe's placement was related to the company's business, Ruikang Pharmaceutical staff responded that it was unclear, or the announcement still prevailed. “This is a very sudden incident.” “The company has a perfect governance structure and internal control mechanism. Apart from Mr. Li Zhe, directors, supervisors and other senior management personnel all perform their duties normally. As of the disclosure date of this announcement, the company's board of directors and supervisors are operating normally, and the production and operation order of the company and its subsidiaries is normal. This matter will not have a significant impact on the normal production and operation of the company.” According to Ruikang Pharmaceutical.

On July 3, Ruikang Pharmaceutical opened lower. As of press release, it reported 2.97 yuan/share, a decrease of 1.33%. Earlier, Ruikang Pharmaceutical announced the news that Li Zhe, director, board secretary and vice president of the company, had been placed in lien. Regarding questions such as whether Li Zhe's placement was related to the company's business, Ruikang Pharmaceutical staff responded that it was unclear, or the announcement still prevailed. “This is a very sudden incident.” “The company has a perfect governance structure and internal control mechanism. Apart from Mr. Li Zhe, directors, supervisors and other senior management personnel all perform their duties normally. As of the disclosure date of this announcement, the company's board of directors and supervisors are operating normally, and the production and operation order of the company and its subsidiaries is normal. This matter will not have a significant impact on the normal production and operation of the company.” According to Ruikang Pharmaceutical.